Cambridge Investment Research Advisors
HRTX icon

Cambridge Investment Research Advisors’s Heron Therapeutics HRTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Sell
22,297
-4,125
-16% -$4.78K ﹤0.01% 3896
2025
Q4 		$34K Sell
26,422
-200
-0.8% -$247 ﹤0.01% 3772
2025
Q3 		$34K Sell
26,622
-1,345
-5% -$2.13K ﹤0.01% 3671
2025
Q2 		$58K Buy
27,967
+100
+0.4% +$204 ﹤0.01% 3528
2025
Q1 		$61K Buy
27,867
+17,500
+169% +$34K ﹤0.01% 3393
2024
Q4 		$16K Sell
10,367
-1,300
-11% -$2.11K ﹤0.01% 3432
2024
Q3 		$23K Sell
11,667
-3,200
-22% -$7.64K ﹤0.01% 3361
2024
Q2 		$52K Buy
14,867
+4,000
+37% +$12.3K ﹤0.01% 3215
2024
Q1 		$30K Sell
10,867
-1,000
-8% -$2.51K ﹤0.01% 3247
2023
Q4 		$20K Sell
11,867
-3,750
-24% -$4.13K ﹤0.01% 3143
2023
Q3 		$16K Sell
15,617
-1,900
-11% -$2.7K ﹤0.01% 3092
2023
Q2 		$20K Sell
17,517
-500
-3% -$892 ﹤0.01% 3125
2023
Q1 		$27K Buy
18,017
+700
+4% +$1.75K ﹤0.01% 3084
2022
Q4 		$43K Sell
17,317
-1,000
-5% -$3.22K ﹤0.01% 2996
2022
Q3 		$77K Hold
18,317
– – ﹤0.01% 2893
2022
Q2 		$51K Sell
18,317
-1,500
-8% -$6.02K ﹤0.01% 2940
2022
Q1 		$113K Buy
19,817
+41
+0.2% +$300 ﹤0.01% 2999
2021
Q4 		$181K Buy
19,776
+4,540
+30% +$46.4K ﹤0.01% 2917
2021
Q3 		$163K Buy
15,236
+31
+0.2% +$377 ﹤0.01% 2860
2021
Q2 		$236K Buy
+15,205
New +$242K ﹤0.01% 2675

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Cambridge Investment Research Advisors's HRTX Position: Q1 2026 in Review

Cambridge Investment Research Advisors reduced its Heron Therapeutics (HRTX) stake by 16% in Q1 2026, selling an estimated $4.78K and leaving 22,297 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #3896.

Cambridge Investment Research Advisors first reported a position in HRTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $236K in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Cambridge Investment Research Advisors held 22,297 shares of Heron Therapeutics worth $18K as of Q1 2026.
  • Cambridge Investment Research Advisors sold 4,125 Heron Therapeutics shares in Q1 2026, an estimated $4.78K.
  • Heron Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3896 holding.
  • Cambridge Investment Research Advisors first reported a position in Heron Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Cambridge Investment Research Advisors's Heron Therapeutics position peaked at $236K in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.